MX2016015930A - Biomarcador de hipertension pulmonar. - Google Patents

Biomarcador de hipertension pulmonar.

Info

Publication number
MX2016015930A
MX2016015930A MX2016015930A MX2016015930A MX2016015930A MX 2016015930 A MX2016015930 A MX 2016015930A MX 2016015930 A MX2016015930 A MX 2016015930A MX 2016015930 A MX2016015930 A MX 2016015930A MX 2016015930 A MX2016015930 A MX 2016015930A
Authority
MX
Mexico
Prior art keywords
pulmonary hypertension
ccl21
remodelling
biomarker
upregulated
Prior art date
Application number
MX2016015930A
Other languages
English (en)
Inventor
Rowlands Marianna
Anne Jeanne Marie Tessier Clemence
Andrew Whittaker Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016015930A publication Critical patent/MX2016015930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La hipertensión pulmonar es una enfermedad progresiva de diversos orígenes que se asocia con remodelación vascular y produce insuficiencia cardiaca derecha. La evidencia acumulada indica funciones importantes de células inmunes y quimiocinas inflamatorias en la patogénesis y progresión de la hipertensión pulmonar. Los presentes inventores identificaron CCL21 como un biomarcador de la eficacia de anti-remodelación para hipertensión pulmonar. Se encontró que CCL21 es muy sensible y específico para discriminar entre pacientes de hipertensión pulmonar y controles equiparados. El CCL21 fue regulado positivamente en la hipertensión pulmonar y regulado negativamente con tratamiento con un agente anti-remodelación.
MX2016015930A 2014-06-03 2015-05-29 Biomarcador de hipertension pulmonar. MX2016015930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170962 2014-06-03
PCT/IB2015/054082 WO2015186037A1 (en) 2014-06-03 2015-05-29 Pulmonary hypertension biomarker

Publications (1)

Publication Number Publication Date
MX2016015930A true MX2016015930A (es) 2017-04-11

Family

ID=50842165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015930A MX2016015930A (es) 2014-06-03 2015-05-29 Biomarcador de hipertension pulmonar.

Country Status (11)

Country Link
US (3) US20170088897A1 (es)
EP (1) EP3152327B1 (es)
JP (1) JP6622722B2 (es)
KR (1) KR20170013261A (es)
CN (1) CN106460059B (es)
AU (1) AU2015270185B2 (es)
CA (1) CA2950527A1 (es)
EA (1) EA201692350A1 (es)
ES (1) ES2747381T3 (es)
MX (1) MX2016015930A (es)
WO (1) WO2015186037A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3537962A4 (en) * 2016-11-10 2019-11-27 Auburn University METHOD AND SYSTEM FOR ASSESSING A BLOOD VESSEL
CN106978485A (zh) * 2017-03-22 2017-07-25 首都医科大学 卵泡抑素样蛋白1对肺动脉高压的保护作用
WO2018213800A1 (en) * 2017-05-19 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension
CN107436333B (zh) * 2017-09-05 2019-12-20 中国医学科学院阜外医院 精胺作为标志物在制备肺动脉高压的诊断产品中的应用及医疗器械
WO2022202950A1 (ja) * 2021-03-25 2022-09-29 中外製薬株式会社 肺動脈性肺高血圧症患者の選定方法およびバイオマーカー
CN113493829B (zh) * 2021-09-09 2021-11-12 中日友好医院(中日友好临床医学研究所) 生物标志物在肺动脉高压诊疗中的应用
CN116148471B (zh) * 2022-11-01 2024-05-07 中南大学 肺动脉高压的生物标志物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US20060019272A1 (en) * 2004-05-03 2006-01-26 The Regents Of The University Of Colorado Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR101362951B1 (ko) * 2007-04-26 2014-02-28 동국대학교 산학협력단 기미 형성 예지방법 및 기미 형성 예지용 진단 키트
WO2009123730A1 (en) * 2008-04-02 2009-10-08 The Trustees Of The University Of Pennsylvania Methods for diagnosis and prognosis of pulmonary hypertension
CN101318932A (zh) * 2008-07-15 2008-12-10 东华大学 2′-羧基-5′-氟联苯衍生物、其制备及应用
WO2011080050A2 (en) * 2009-12-11 2011-07-07 Novartis Ag Binding molecules
NZ616308A (en) * 2011-04-08 2016-03-31 Biogen Ma Inc Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof

Also Published As

Publication number Publication date
ES2747381T3 (es) 2020-03-10
JP6622722B2 (ja) 2019-12-18
CA2950527A1 (en) 2015-12-10
EP3152327B1 (en) 2019-06-26
US20170088897A1 (en) 2017-03-30
KR20170013261A (ko) 2017-02-06
AU2015270185B2 (en) 2018-07-05
US20200002768A1 (en) 2020-01-02
CN106460059A (zh) 2017-02-22
AU2015270185A1 (en) 2016-12-01
WO2015186037A1 (en) 2015-12-10
EA201692350A1 (ru) 2017-04-28
JP2017519498A (ja) 2017-07-20
CN106460059B (zh) 2021-07-13
EP3152327A1 (en) 2017-04-12
US20220389507A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
MX2016015930A (es) Biomarcador de hipertension pulmonar.
IL286282A (en) Use of palinabolin in combination with immune checkpoint inhibitors
HK1250990A1 (zh) 凝血因子xi抗體及使用方法
GEP20237538B (en) Pd-1-binding molecules and methods of use thereof
IL280619A (en) Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
IL249223A0 (en) Mth1 inhibitors for the treatment of inflammatory and autoimmune conditions
MX2021012636A (es) Terapeuticos dirigidos a la glucosa.
EP3464638A4 (en) USE OF BIOMARKERS TO DETERMINE SENSITIVITY TO TREATMENT OF A DISEASE
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
IL251477A0 (en) Anti-ang2 antibodies and methods of use
IL255440A0 (en) Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
HK1218315A1 (zh) 試劑盒及其在生殖道病原體擴增檢測中的用途
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
PL3137622T3 (pl) Sposoby redukowania spadku pojemności życiowej
IL266116A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use
IL249174A0 (en) Genetic changes associated with autism and autistic phenotype and methods for diagnosing and treating autism
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
PL3107554T3 (pl) Przeciwciało dla odchylenia proporcji płci i sposoby jego zastosowania
GB2535562B8 (en) Hydrogel compositions and their use in the treatment of symptoms induced by hypertrophic scars
BALCI et al. Evaluation of the sexual assault crimes in Muğla Forensic Medicine Department
Chandran CK et al. Water Sensitive Urban Design: Investigating Opportunities for Thiruvananthapuram.
EA201890489A1 (ru) Car макрофагов (moto-car) в иммунотерапии
AR104993A1 (es) Composiciones comprendiendo cepas bacterianas del género parabacteroides
TH1501004430A (th) แอนทิบอดีแอนทิ-il-17a และการใช้ของสิ่งเหล่านั้นในการรักษาความผิดปกติ เหตุโรคภูมิต้านตนเองและเหตุอักเสบ